Novo Nordisk has announced the termination of two separate clinical trials for a drug designed to combat inflammation in hopes of improving cardiovascular health. The company revealed that both the HERMES and ATHENA trials for its medication, known as ziltivekimab, were halted after an independent data monitoring committee determined that the studies were unlikely to meet their primary goals. Investigators involved in the process were notified of the decision this past Friday.
This latest setback represents a significant disappointment for a specific therapeutic approach that seeks to treat heart disease by targeting inflammatory markers. While reducing inflammation was long thought to be a viable pathway toward preventing serious cardiac events, these results suggest that doing so may not translate into tangible patient benefits in every case.
The cancellation of these two trials follows a previous failure during the ZEUS study. In that instance, researchers observed that while ziltivekimab successfully lowered indicators of inflammation within the body, it failed to actually reduce the overall risk of major clinical complications such as heart attacks or death. This pattern suggests a persistent gap between biological success and actual medical outcomes for this particular drug candidate.
